Grant: CIHR-ICR / Cancer Research Society Partnership - Res. Grants-Survivorship

Lung cancer results in the most deaths of all cancer types in Canada. Even when detected early and removed by surgery, lung cancer often recurs. We can’t accurately predict who will have recurrence, such that we don’t know who is cured by surgery and who would benefit from additional treatment such as chemotherapy. There are particularly few tools for recurrence prediction for less common lung cancer types. Lung squamous cell carcinoma (LUSC) is the second most common lung cancer type and has different recurrence patterns than other lung cancers. We aim to develop clinically useful methods for predicting LUSC recurrence by mapping the types and activities of cells in cancer biopsies. This data will be used for new clinical trials, to reduce unnecessary treatments and increase curative outcomes for patients at high risk of recurrence.